A first-in-human, phase l study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma.
Year: 2010
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: S. Dolly, A. J. Wagner, J. C. Bendell, Y. Yan, J. A. Ware, K. E. Mazina, S. N. Holden, M. K. Derynck, J. S. De Bono, H. A. Burris
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2273066532